[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 32 of about 32
1. Bunworasate U, Arnouk H, Minderman H, O'Loughlin KL, Sait SN, Barcos M, Stewart CC, Baer MR: Erythropoietin-dependent transformation of myelodysplastic syndrome to acute monoblastic leukemia. Blood; 2001 Dec 1;98(12):3492-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erythropoietin-dependent transformation of myelodysplastic syndrome to acute monoblastic leukemia.
  • Acute monoblastic leukemia (acute myeloid leukemia [AML], French-American-British type M5a) with leukemia cutis developed in a patient 6 weeks after the initiation of erythropoietin (EPO) therapy for refractory anemia with ringed sideroblasts.
  • [MeSH-major] Erythropoietin / adverse effects. Leukemia, Monocytic, Acute / chemically induced. Myelodysplastic Syndromes / pathology
  • [MeSH-minor] Aged. Anemia, Sideroblastic / drug therapy. Anemia, Sideroblastic / pathology. Antigens, CD13 / analysis. Antigens, CD45 / analysis. Bone Marrow / pathology. Flow Cytometry. Humans. Male. Receptors, Erythropoietin / analysis. Skin / pathology


2. Hayakawa S, Kimura T, Saeki K, Koyama Y, Aoyagi Y, Noro T, Nakamura Y, Isemura M: Apoptosis-inducing activity of high molecular weight fractions of tea extracts. Biosci Biotechnol Biochem; 2001 Feb;65(2):459-62
Hazardous Substances Data Bank. Green tea .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High molecular weight fractions of green tea, black tea, oolong tea, and pu-erh tea were found to induce apoptosis in human monoblastic leukemia U937 cells by examination of their ability to inhibit cell proliferation and to induce apoptotic body formation and DNA ladder formation.
  • [MeSH-minor] Catechin / analogs & derivatives. Catechin / pharmacology. DNA Fragmentation / drug effects. Humans. Molecular Weight. Neoplasms / prevention & control. Plant Extracts / chemistry. Plant Extracts / pharmacology. Stomach Neoplasms / diet therapy. Stomach Neoplasms / pathology. Tumor Cells, Cultured. U937 Cells

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11302190.001).
  • [ISSN] 0916-8451
  • [Journal-full-title] Bioscience, biotechnology, and biochemistry
  • [ISO-abbreviation] Biosci. Biotechnol. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Plant Extracts; 0 / Tea; 8R1V1STN48 / Catechin; BQM438CTEL / epigallocatechin gallate
  •  go-up   go-down


3. Takahashi T, Tsukuda H, Kimura H, Yoshimoto M, Tsujisaki M: Extramedullary relapse of AML with t(9;11)(p22;q23) associated with clonal evolution from trisomy 8 into tetrasomy 8. Intern Med; 2010;49(5):447-51
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extramedullary relapse of AML with t(9;11)(p22;q23) associated with clonal evolution from trisomy 8 into tetrasomy 8.
  • This report describes a patient with extramedullary relapse of acute myeloid leukemia (AML) without involving bone marrow.
  • A 57-year-old man was diagnosed as having acute monoblastic leukemia with t(9;11)(p22;q23) and trisomy 8.
  • Ten months after achieving complete response (CR) with chemotherapy, masses developed in his left forearm and in the back of his thigh, preceded by enigmatic peripheral neurological symptoms.
  • [MeSH-major] Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 8 / genetics. Chromosomes, Human, Pair 9 / genetics. Leukemia, Myeloid, Acute / genetics. Sarcoma, Myeloid / diagnosis. Sarcoma, Myeloid / genetics. Trisomy / genetics
  • [MeSH-minor] Chromosome Aberrations. Drug Therapy. Forearm. Humans. Male. Middle Aged. Recurrence. Thigh

  • Genetic Alliance. consumer health - Chromosome 9, Trisomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20190481.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


Advertisement
4. Charrad RS, Gadhoum Z, Qi J, Glachant A, Allouche M, Jasmin C, Chomienne C, Smadja-Joffe F: Effects of anti-CD44 monoclonal antibodies on differentiation and apoptosis of human myeloid leukemia cell lines. Blood; 2002 Jan 1;99(1):290-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of anti-CD44 monoclonal antibodies on differentiation and apoptosis of human myeloid leukemia cell lines.
  • Acute myeloid leukemia (AML) is a heterogeneous leukemia characterized by the blockage of myeloid differentiation at different stages, which define distinct AML subtypes.
  • Therefore, to find relevant in vitro cellular models for further studying the mechanisms involved in CD44-induced differentiation, we investigated whether CD44 ligation with A3D8 and H90 mAbs can induce terminal differentiation of THP-1, NB4, and HL60 cells, each interesting models of AML-M5 (monoblastic subtype), AML-M3 (promyelocytic subtype), and AML-M2 (myeloblastic subtype), respectively.
  • Finally, our results demonstrate for the first time that it is possible to reverse the leukemic blockage of KG1a cells by using both an anti-CD44 mAb and retinoic acid.
  • This result may provide a new experimental basis for a differentiative therapy in AML-M0 patients.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Antigens, CD44 / physiology. Apoptosis. Cell Differentiation. Leukemia, Myeloid, Acute / pathology
  • [MeSH-minor] Cell Division / drug effects. Granulocytes / pathology. HL-60 Cells / pathology. Humans. Tretinoin / pharmacology. Tumor Cells, Cultured


5. Bachmeyer C, Turc Y, Fraitag S, Delmer A, Aractingi S: [Aleukemic monoblastic leukemia cutis]. Ann Dermatol Venereol; 2003 Aug-Sep;130(8-9 Pt 1):773-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Aleukemic monoblastic leukemia cutis].
  • BACKGROUND: The diagnostic and prognostic value of specific cutaneous lesions in acute leukemia is well-known.
  • We report the case of a patient with cutaneous lesions of acute monoblastic leukemia whereas peripheral blood was normal and massive infiltration of dermis was demonstrated.
  • Histological examination with appropriate immunostaining led to the diagnosis of specific cutaneous lesions of acute monoblastic leukemia.
  • Cutaneous lesions disappeared with chemotherapy.
  • DISCUSSION: Specific cutaneous lesions may be isolated during acute leukemia, and called aleukemic leukemia cutis.
  • [MeSH-major] Leukemia / pathology. Leukemia, Monocytic, Acute / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14576608.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


6. Pullarkat V, Veliz L, Chang K, Mohrbacher A, Teotico AL, Forman SJ, Slovak ML: Therapy-related, mixed-lineage leukaemia translocation-positive, monoblastic myeloid sarcoma of the uterus. J Clin Pathol; 2007 May;60(5):562-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related, mixed-lineage leukaemia translocation-positive, monoblastic myeloid sarcoma of the uterus.
  • These tumours can, on occasion, occur without concurrent or antecedent leukaemia.
  • An unusual case of therapy-related acute myeloid leukaemia (t-AML) presenting as isolated monoblastic myeloid sarcoma of the uterus in a patient who had received adjuvant chemotherapy for breast cancer is presented.
  • Fluorescence in situ hybridisation analysis performed on paraffin-wax-embedded tumour tissue revealed a mixed-lineage leukaemia (MLL) gene rearrangement, supporting the association of this malignancy with prior chemotherapy.
  • This case illustrates that t-AML can rarely present as isolated extramedullary tumours, and the detection of specific chromosomal abnormalities in these myeloid sarcomas can be useful for risk assessment and guiding definitive therapy.

  • Genetic Alliance. consumer health - Myeloid sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2000 Nov;114(5):807-11 [11068557.001]
  • [Cites] Leuk Lymphoma. 2001 Apr;41(3-4):255-76 [11378539.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):1967-72 [12057901.001]
  • [Cites] Leuk Lymphoma. 2002 Nov;43(11):2151-3 [12533040.001]
  • [Cites] Int J Surg Pathol. 2003 Oct;11(4):271-82 [14615822.001]
  • [Cites] Leukemia. 2005 Feb;19(2):183-90 [15618964.001]
  • [Cites] Urology. 1986 Mar;27(3):268-70 [3082059.001]
  • [Cites] Gynecol Oncol. 1992 Jul;46(1):128-37 [1634133.001]
  • [Cites] Blood. 1993 Dec 15;82(12):3705-11 [8260707.001]
  • [Cites] Am J Clin Pathol. 1995 Oct;104(4):431-43 [7572794.001]
  • [Cites] Am J Surg Pathol. 1997 Oct;21(10):1156-65 [9331287.001]
  • [Cites] Leuk Res. 2004 Nov;28(11):1165-9 [15380340.001]
  • (PMID = 17513515.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA030206; United States / NCI NIH HHS / CA / 2 P01 CA030206-24A1; United States / NCI NIH HHS / CA / 5P30 CA33572
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1994540
  •  go-up   go-down


7. Saito B, Nakamaki T, Nakashima H, Usui T, Hattori N, Kawakami K, Tomoyasu S: Reversible posterior leukoencephalopathy syndrome after repeat intermediate-dose cytarabine chemotherapy in a patient with acute myeloid leukemia. Am J Hematol; 2007 Apr;82(4):304-6
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reversible posterior leukoencephalopathy syndrome after repeat intermediate-dose cytarabine chemotherapy in a patient with acute myeloid leukemia.
  • Acute monoblastic leukemia was diagnosed.
  • Two subsequent courses of consolidation chemotherapy consisted of conventional doses of cytarabine and intermediate-dose cytarabine.
  • No infiltration of leukemia cells was seen.
  • RPLS in the present case was unlikely to have been caused by direct neurotoxicity because (1) the doses of cytarabine (500 mg/m(2); total dose 9.2 g) were much smaller than those in reported cases and were repeatedly infused until RPLS developed;.
  • (2) the RPLS developed 21 days after the final infusion of cytarabine, a much longer period than previously reported;.
  • These details suggest not only that direct cerebral neurotoxicity of cytarabine but also that some type of allergic response may have been involved in the development of RPLS.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Brain Diseases / chemically induced. Cytarabine / adverse effects. Leukemia, Monocytic, Acute / drug therapy. Neurotoxicity Syndromes / etiology
  • [MeSH-minor] Drug Hypersensitivity. Humans. Male. Middle Aged. Syndrome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16947320.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine
  •  go-up   go-down


8. Hull DR, Alexander HD, Markey GM, Lyness RW, Morris TC: Histiocytic lymphoma presenting as a testicular tumour and terminating in acute monoblastic leukaemia. J Clin Pathol; 2000 Oct;53(10):788-90
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histiocytic lymphoma presenting as a testicular tumour and terminating in acute monoblastic leukaemia.
  • Six months later he developed a buccal lesion, which was biopsied and reported as a high grade non-Hodgkin's lymphoma.
  • It responded completely to chemotherapy but within a year he developed a forearm swelling, which was biopsied and imprints made before fixation of the material.
  • Despite further treatment, the patient entered a terminal acute leukaemic phase, the blasts marking as monoblasts.
  • Review of all the biopsies, including molecular investigations and further immunohistochemistry studies performed retrospectively on the original biopsy, demonstrated that this was the same malignant cell line throughout, and we conclude that this is a case of histiocytic lymphoma, initially presenting as a testicular tumour and terminating in acute monoblastic leukaemia.
  • [MeSH-major] Leukemia, Monocytic, Acute / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Testicular Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11064675.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] ENGLAND
  • [Other-IDs] NLM/ PMC1731083
  •  go-up   go-down


9. Yamada R, Horikawa K, Ishihara S, Hoshino K, Kawaguchi T, Iyama K, Mitsuya H, Asou N: Successful treatment of Aspergillus liver abscesses in a patient with acute monoblastic leukemia using combination antifungal therapy including micafungin as a key drug. Int J Hematol; 2010 May;91(4):711-5
MedlinePlus Health Information. consumer health - Hepatitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of Aspergillus liver abscesses in a patient with acute monoblastic leukemia using combination antifungal therapy including micafungin as a key drug.
  • While anti-cancer chemotherapy has improved the survival of patients with hematologic malignancies, it has also exposed such patients to the risk of life-threatening infection due to neutropenia.
  • In intensive chemotherapy for leukemia, invasive aspergillosis resulting in death is infrequently observed.
  • In such cases, aggressive diagnostic and therapeutic intervention is required.
  • Herein, we report a case of Aspergillus liver abscesses in a patient with acute monoblastic leukemia.
  • The patient presented with febrile neutropenia and concomitantly with an elevated serum beta-D: -glucan level during chemotherapy.
  • Therefore, our clinical experience suggests that the serum test is useful for the rapid diagnosis of invasive aspergillosis, especially in deep tissues, and that combination antifungal therapy with micafungin should be considered when initial monotherapy for fungal infection shows an insufficient effect.
  • [MeSH-major] Antifungal Agents / administration & dosage. Aspergillosis / drug therapy. Echinocandins / administration & dosage. Hepatitis / drug therapy. Leukemia, Monocytic, Acute / complications. Lipopeptides / administration & dosage. Liver Abscess / drug therapy
  • [MeSH-minor] Drug Therapy, Combination. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Acute Monoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Infect Dis. 2008 Feb 1;46(3):327-60 [18177225.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):764-71 [10072411.001]
  • [Cites] Ann Pharmacother. 2001 Jun;35(6):720-9 [11408991.001]
  • [Cites] Ann Hematol. 1997 Jul-Aug;75(1-2):9-16 [9322678.001]
  • [Cites] Acta Biomed. 2006;77 Suppl 2:10-3 [16918060.001]
  • [Cites] Cancer. 2007 Dec 15;110(12 ):2740-6 [17941026.001]
  • [Cites] J Clin Microbiol. 2004 Jun;42(6):2733-41 [15184460.001]
  • [Cites] Clin Vaccine Immunol. 2008 Oct;15(10):1625-8 [18667632.001]
  • [Cites] Haematologia (Budap). 2001;31(1):73-80 [11345409.001]
  • [Cites] Clin Infect Dis. 2008 Mar 15;46(6):878-85 [18260755.001]
  • [Cites] J Infect. 2006 Nov;53(5):337-49 [16678903.001]
  • [Cites] Lancet. 2003 Oct 4;362(9390):1142-51 [14550704.001]
  • [Cites] Haematologica. 2006 Aug;91(8):1068-75 [16885047.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1025-32 [12569602.001]
  • [Cites] Cancer. 1975 Dec;36(6):2271-6 [1060508.001]
  • [Cites] Drug Resist Updat. 2003 Aug;6(4):197-218 [12962685.001]
  • [Cites] Clin Infect Dis. 2007 Feb 15;44(4):531-40 [17243056.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Sep;25(9):732-4 [12972810.001]
  • [Cites] Clin Infect Dis. 2002 Jan 1;34(1):7-14 [11731939.001]
  • [Cites] Haematologica. 2001 Aug;86(8):862-70 [11522544.001]
  • [Cites] Clin Pharmacokinet. 2006;45(7):649-63 [16802848.001]
  • [Cites] Clin Infect Dis. 2000 Nov;31(5):1253-7 [11073760.001]
  • [Cites] J Clin Pharmacol. 2005 Oct;45(10):1145-52 [16172179.001]
  • [Cites] J Clin Pathol. 1960 Sep;13:396-413 [13707576.001]
  • [Cites] Clin Infect Dis. 2004 Sep 15;39(6):797-802 [15472810.001]
  • [Cites] J Infect Dis. 2006 Oct 1;194(7):1008-18 [16960790.001]
  • [Cites] Ann Hematol. 2006 Sep;85(9):621-3 [16758192.001]
  • [Cites] Am J Hematol. 2001 Dec;68(4):231-6 [11754411.001]
  • [Cites] Clin Infect Dis. 2003 Mar 1;36(5):630-7 [12594645.001]
  • (PMID = 20352380.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Echinocandins; 0 / Lipopeptides; R10H71BSWG / micafungin
  •  go-up   go-down


10. Demircioğlu F, Oren H, Yilmaz S, Arslansoyu S, Eren S, Irken G: Chemotherapy-induced acral erythema in a pediatric patient with acute monoblastic leukemia. Pediatr Hematol Oncol; 2008 Apr-May;25(3):211-5
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy-induced acral erythema in a pediatric patient with acute monoblastic leukemia.
  • Chemotherapy-induced acral erythema or palmoplantar erythrodysesthesia syndrome is a well-defined reaction to some of the chemotherapeutic agents such as methotrexate, cytarabine, doxorubicin, fluorouracil, and bleomycin.
  • The authors present a case of acral erythema in a young patient with acute monoblastic leukemia to emphasize this high-dose chemotherapy-induced side effect, which is rarely seen in children and is usually self-limited.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Erythema / chemically induced. Leukemia, Monocytic, Acute / complications

  • Genetic Alliance. consumer health - Acute Monoblastic Leukemia.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18432504.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 11056-06-7 / Bleomycin; 80168379AG / Doxorubicin; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


11. Bairey O, Kirgner I, Yakobi M, Hamdan A, Ben-Ari Z, Shaklai M: Clinical severe hepatic venoocclusive disease during induction treatment of acute monoblastic leukemia managed with defibrotide. Am J Hematol; 2002 Apr;69(4):281-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical severe hepatic venoocclusive disease during induction treatment of acute monoblastic leukemia managed with defibrotide.
  • Hepatic venoocclusive disease (VOD) is the most common complication of cytoreductive therapy used for stem cell transplantation, but it is rarely encountered during induction treatment of acute leukemia.
  • We describe a patient in whom severe clinical VOD developed shortly after induction treatment for acute monoblastic leukemia.
  • Further consolidation treatment was resumed including high-dose cytosine arabinoside without further complications.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Fibrinolytic Agents / therapeutic use. Hepatic Veno-Occlusive Disease / chemically induced. Hepatic Veno-Occlusive Disease / drug therapy. Leukemia, Monocytic, Acute / drug therapy. Polydeoxyribonucleotides / therapeutic use

  • Genetic Alliance. consumer health - Acute Monoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • (PMID = 11921023.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fibrinolytic Agents; 0 / Polydeoxyribonucleotides; 04079A1RDZ / Cytarabine; 438HCF2X0M / defibrotide; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


12. Pawarode A, Baer MR, Padmanabhan S, Wallace PK, Barcos M, Sait SN, Block AW, Wetzler M, Battiwalla M: Simultaneous presentation of acute monoblastic leukemia and mantle cell lymphoma: case report and review of the literature. Leuk Lymphoma; 2005 Dec;46(12):1813-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous presentation of acute monoblastic leukemia and mantle cell lymphoma: case report and review of the literature.
  • This paper reports a 73-year old woman with simultaneous presentation of acute monoblastic leukemia (acute myeloid leukemia (AML), French-American-British (FAB) type M5a) and mantle cell lymphoma.
  • The patient received infusional cytarabine, daunorubicin and etoposide chemotherapy, with complete remission of both the AML and the mantle cell leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Monocytic, Acute / complications. Lymphoma, Mantle-Cell / complications
  • [MeSH-minor] Aged. Antigens, CD / blood. Biopsy. Female. Humans. Lymphocytes / pathology. Treatment Outcome


13. Prayongratana K, Kulpraneet M, Panichchob P, Tantisiriwat W: Acute monoblastic leukemia with t(10;11)(p12;q23) presenting with pulmonary involvement: a case report and literature review. J Med Assoc Thai; 2008 Apr;91(4):559-63
Hazardous Substances Data Bank. CASPOFUNGIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute monoblastic leukemia with t(10;11)(p12;q23) presenting with pulmonary involvement: a case report and literature review.
  • Bone marrow study was consistent with acute monoblastic leukemia.
  • Induction chemotherapy with 7 + 3 regimen was administered to halt the progression of leukemic pulmonary infiltration.
  • Although there was clinical improvement, the chest radiograph developed crescent formation in the right upper lung field.
  • The literature review showed that the appropriate treatment for the patients with t(10;11)(p12;q23) was HSCT, but there was no data concerning correlation of t(10;11)(p12;q23) and pulmonary infiltration.
  • This may be due to the low incidence of leukemic infiltration of acute leukemia patients, which is 0.48% and 3.06% in acute myeloid leukemia and acute monoblastic leukemia, respectively.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Monocytic, Acute / pathology. Lung Neoplasms / secondary
  • [MeSH-minor] Adult. Antibiotics, Antineoplastic / therapeutic use. Antifungal Agents / therapeutic use. Antimetabolites, Antineoplastic / therapeutic use. Aspergillosis, Allergic Bronchopulmonary / pathology. Bronchoalveolar Lavage. Cytarabine / therapeutic use. Echinocandins / therapeutic use. Humans. Idarubicin / therapeutic use. Male. Pyrimidines / therapeutic use. Thailand. Triazoles / therapeutic use. Voriconazole

  • Genetic Alliance. consumer health - Acute Monoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18556867.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antifungal Agents; 0 / Antimetabolites, Antineoplastic; 0 / Echinocandins; 0 / Pyrimidines; 0 / Triazoles; 04079A1RDZ / Cytarabine; F0XDI6ZL63 / caspofungin; JFU09I87TR / Voriconazole; ZRP63D75JW / Idarubicin
  • [Number-of-references] 22
  •  go-up   go-down


14. Stasik C, Ganguly S, Cunningham MT, Hagemeister S, Persons DL: Infant acute lymphoblastic leukemia with t(11;16)(q23;p13.3) and lineage switch into acute monoblastic leukemia. Cancer Genet Cytogenet; 2006 Jul 15;168(2):146-9
Genetic Alliance. consumer health - Acute Monoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infant acute lymphoblastic leukemia with t(11;16)(q23;p13.3) and lineage switch into acute monoblastic leukemia.
  • Rearrangements of the mixed-lineage leukemia (MLL) gene have been associated with a poor prognosis in infant acute lymphoblastic leukemia (ALL).
  • Previously, MLL translocations involving the CREP-binding protein (CREBBP) gene at chromosome band 16p13.3 have primarily been reported in treatment-related acute myeloid leukemia, after chemotherapy for other primary malignancies using topoisomerase II inhibitors.
  • We report a case of de novo infant ALL with t(11;16)(q23;p13.3).
  • After chemotherapy, this patient developed an acute monoblastic leukemia (M5b) with retention of the t(11;16)(q23;p13.3), indicating that this is a lineage switch of the original leukemic clone.
  • [MeSH-major] Cell Lineage. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 16 / genetics. Leukemia, Monocytic, Acute / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16843104.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Kurosawa H, Tsuboi T, Shimaoka H, Okuya M, Nakajima D, Matsunaga T, Hagisawa S, Sato Y, Sugita K, Eguchi M: [Long-term remission in an acute monoblastic leukemia patient with down syndrome after cord blood transplantation]. Rinsho Ketsueki; 2005 Apr;46(4):274-7
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term remission in an acute monoblastic leukemia patient with down syndrome after cord blood transplantation].
  • A 4-year-old boy with Down syndrome (DS) was diagnosed as having acute monoblastic leukemia (AML-M5a).
  • Leukemic cells were CD33+, CD56+ and CD4+, with t(9;11) on cytogenetic analysis and MLL gene rearrangement.
  • After 2 courses of induction therapy using an AML 99-Down protocol failed to obtain complete remission, the patient received cord blood transplantation from an HLA-matched donor (CBT) following a conditioning regimen comprising total body irradiation and cyclophosphamide.
  • Stem cell transplantation may not be indicated for AML patient with DS in first remission, who display a high rate of life-threatening and fatal toxicity on therapy.
  • This patient remained well controlled in complete remission for 4 years, representing a rare case of DS with chemotherapy-resistant AML successfully treated with a CBT.
  • [MeSH-major] Cord Blood Stem Cell Transplantation. Down Syndrome / complications. Leukemia, Monocytic, Acute / therapy
  • [MeSH-minor] Child, Preschool. Cyclosporine / administration & dosage. Graft vs Host Disease / prevention & control. Humans. Male. Remission Induction. Time Factors. Transplantation Conditioning. Treatment Outcome


16. Kim A, Cook R, Wainwright L, Biegel J, Schuster S, Wasik M: Dramatic response of acute monoblastic leukemia to a single dose of docetaxel. Leuk Lymphoma; 2008 Mar;49(3):577-80
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dramatic response of acute monoblastic leukemia to a single dose of docetaxel.
  • [MeSH-major] Leukemia, Monocytic, Acute / drug therapy. Neoplasms, Second Primary / drug therapy. Taxoids / therapeutic use
  • [MeSH-minor] Bone Marrow Examination. Breast Neoplasms / pathology. Breast Neoplasms / therapy. Female. Humans. Middle Aged. Remission Induction / methods

  • Genetic Alliance. consumer health - Acute Monoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18297537.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel
  •  go-up   go-down


17. Wilda M, Perez AV, Bruch J, Woessmann W, Metzler M, Fuchs U, Borkhardt A: Use of MLL/GRAF fusion mRNA for measurement of minimal residual disease during chemotherapy in an infant with acute monoblastic leukemia (AML-M5). Genes Chromosomes Cancer; 2005 Aug;43(4):424-6
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of MLL/GRAF fusion mRNA for measurement of minimal residual disease during chemotherapy in an infant with acute monoblastic leukemia (AML-M5).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. DNA-Binding Proteins / genetics. GTPase-Activating Proteins / genetics. Leukemia, Myeloid, Acute / diagnosis. Oncogene Proteins, Fusion / genetics. Proto-Oncogenes / genetics. RNA, Messenger / genetics. Transcription Factors / genetics
  • [MeSH-minor] Cytarabine / administration & dosage. Etoposide / administration & dosage. Histone-Lysine N-Methyltransferase. Humans. Idarubicin / administration & dosage. In Situ Hybridization, Fluorescence. Infant. Male. Mitoxantrone / administration & dosage. Myeloid-Lymphoid Leukemia Protein. Neoplasm, Residual

  • Genetic Alliance. consumer health - Acute Monoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Genes Chromosomes Cancer. 2004 Dec;41(4):400-4 [15382263.001]
  • (PMID = 15852479.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ARHGAP26 protein, human; 0 / DNA-Binding Proteins; 0 / GTPase-Activating Proteins; 0 / MLL protein, human; 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; 0 / Transcription Factors; 04079A1RDZ / Cytarabine; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; ZRP63D75JW / Idarubicin
  •  go-up   go-down


18. Crews KR, Wimmer PS, Hudson JQ, Howard SC, Ribeiro RC, Razzouk BI: Pharmacokinetics of 2-chlorodeoxyadenosine in a child undergoing hemofiltration and hemodialysis for acute renal failure. J Pediatr Hematol Oncol; 2002 Nov;24(8):677-80
Hazardous Substances Data Bank. CLADRIBINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors describe the clinical course and the pharmacokinetics of 2-CdA in a child with acute monoblastic leukemia who experienced acute renal failure during treatment with cytarabine and 2-CdA.
  • The average clearance rate, reflecting systemic clearance and clearance by continuous venovenous hemofiltration and hemodialysis, was 12.4 L/hour per m for the first 3 days of 2-CdA therapy.
  • Because high 2-CdA plasma concentrations were observed in this patient, clinicians are advised to exercise caution when using this drug in patients with renal dysfunction.
  • [MeSH-major] Acute Kidney Injury / metabolism. Antimetabolites, Antineoplastic / pharmacokinetics. Cladribine / pharmacokinetics. Hemofiltration. Leukemia, Monocytic, Acute / drug therapy. Renal Dialysis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Aspergillosis / complications. Child. Combined Modality Therapy. Cytarabine / administration & dosage. Cytarabine / adverse effects. Daunorubicin / administration & dosage. Etoposide / administration & dosage. Fatal Outcome. Humans. Leukapheresis. Male. Metabolic Clearance Rate. Recombinant Proteins / therapeutic use. Remission Induction. Urate Oxidase / therapeutic use

  • MedlinePlus Health Information. consumer health - Dialysis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12439044.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 21765
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Recombinant Proteins; 04079A1RDZ / Cytarabine; 47M74X9YT5 / Cladribine; 6PLQ3CP4P3 / Etoposide; EC 1.7.3.3 / Urate Oxidase; ZS7284E0ZP / Daunorubicin; DAV regimen
  •  go-up   go-down


19. Nadano D, Aoki C, Yoshinaka T, Irie S, Sato TA: Electrophoretic characterization of ribosomal subunits and proteins in apoptosis: specific downregulation of S11 in staurosporine-treated human breast carcinoma cells. Biochemistry; 2001 Dec 18;40(50):15184-93
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Stimulation of death receptors (Fas on human T-cell leukemia Jurkat cells and tumor necrosis factor receptor-1 on human monoblastic leukemia U937 cells) triggers the specific degradation of 28S ribosomal RNA, and this process may contribute to cell death through the inhibition of protein synthesis.
  • We have developed an analytical method using a polyacrylamide-agarose composite gel to evaluate ribosomal subunits in apoptotic cells (human breast carcinoma MCF-7 cells treated with staurosporine and human 293T cells irradiated with ultraviolet light were used in addition to the two apoptosis systems described above).
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / metabolism. Ribosomal Proteins / metabolism. Staurosporine / pharmacology
  • [MeSH-minor] Amino Acid Sequence. Animals. Apoptosis. Down-Regulation / drug effects. Electrophoresis, Agar Gel. Electrophoresis, Polyacrylamide Gel. Female. Humans. Jurkat Cells. Male. Molecular Sequence Data. Rats. Rats, Sprague-Dawley. Ribosomes / drug effects. Ribosomes / metabolism. Tumor Cells, Cultured. U937 Cells. Ubiquitin / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11735401.001).
  • [ISSN] 0006-2960
  • [Journal-full-title] Biochemistry
  • [ISO-abbreviation] Biochemistry
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ribosomal Proteins; 0 / Ubiquitin; 0 / ribosomal protein S11; H88EPA0A3N / Staurosporine
  •  go-up   go-down


20. Kikuchi H, Kuribayashi F, Kiwaki N, Nakayama T: Curcumin dramatically enhances retinoic acid-induced superoxide generating activity via accumulation of p47-phox and p67-phox proteins in U937 cells. Biochem Biophys Res Commun; 2010 Apr 23;395(1):61-5
Hazardous Substances Data Bank. CURCUMIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we describe that curcumin, a polyphenol responsible for the yellow color of curry spice turmeric, dramatically activates the O(2)(-)-generating system during retinoic acid (RA)-induced differentiation of human monoblastic leukemia U937 cells to macrophage-like cells.
  • Semiquantitative RT-PCR showed that co-treatment with RA and curcumin slightly enhanced gene expressions of the five components compared with those of the RA-treatment only.
  • On the other hand, immunoblot analysis revealed that co-treatment with RA and curcumin caused remarkable accumulation of protein levels of p47-phox (to 7-fold) and p67-phox (to 4-fold) compared with those of the RA-treatment alone.
  • Therefore, it should have the potential as an effective modifier in therapy of leukemia and/or as an immunopotentiator.
  • [MeSH-minor] B-Lymphocytes / drug effects. Cell Line, Tumor. Drug Synergism. Gene Expression / drug effects. Humans. Leukemia / metabolism. Phagocytes / drug effects

  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20346917.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antineoplastic Agents; 0 / Phosphoproteins; 0 / neutrophil cytosol factor 67K; 11062-77-4 / Superoxides; 5688UTC01R / Tretinoin; EC 1.6.3.1 / NADPH Oxidase; EC 1.6.3.1 / neutrophil cytosolic factor 1; IT942ZTH98 / Curcumin
  •  go-up   go-down


21. Pogrebniak A, Hasmann M, Schemainda I, Pelka-Fleischer R, Nuessler V: Cytoprotective features of selenazofurin in hematopoietic cells. Int J Clin Pharmacol Ther; 2002 Aug;40(8):368-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Antineoplastic activity of tiazofurin (Tz) and selenazofurin (Se) depends on their conversion to substances which are analogs of NAD.
  • The therapeutic potential of modulating intracellular NAD levels and activity of NAD-dependent enzymes by concomitant administration of conventional anticancer agents merits further research.
  • Our aim was to investigate the cytotoxic effects of Tz and Se in hematopoietic cells and to test their ability to potentiate the effects of DNA strand-disrupting agents.
  • MATERIAL: THP-1, a cell line, derived from human acute monoblastic leukemia, was used.
  • METHODS: The WST-l test was used to detect the function of NAD(P)-dependent dehydrogenases after exposure of THP-1 cells to Tz or Se.
  • Cytotoxicity of Tz, Se, MNNG and chlorambucil was assessed using the membrane permeability assay (PI test).
  • RESULTS: THP-1 cells were sensitive to cytotoxic effects of Tz and Se, with IC50 values of 2.5 x 10(-5) M for Tz and 2 x 10(-6) M for Se, as determined with the WST-1 test; 10 microM Se induced cell membrane disruption in more than 20% of THP-1 cells 48 hours after commencement of treatment, whereas the same concentration of Tz failed to increase membrane permeability.
  • Pretreatment of THP-1 cells with 0.5 - 1.5 microM Se had no effect on the time course of cell death, induced by treatment with the DNA-damaging agent 1-methyl-3-nitro-1 - nitrosoguanidinium (MNNG) for 36 hours.
  • However, when incubation of THP-1 cells with MNNG was prolonged (72 hours) without changing the incubation medium, pretreatment with Se had the following effects: the relative number of cells that died spontaneously decreased, and the cytotoxicity of MNNG was diminished.
  • CONCLUSIONS: Contrary to other investigations, we here demonstrate that preincubation with Se may partially protect cells from cell death induced by the alkylating agents MNNG and chlorambucil in the THP-1 cell line and in CLL lymphocytes presumably by affecting spontaneous cell death.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Organoselenium Compounds / pharmacology. Organoselenium Compounds / therapeutic use. Ribavirin / analogs & derivatives. Ribonucleosides / pharmacology. Ribonucleosides / therapeutic use
  • [MeSH-minor] Cell Death / drug effects. Cell Line. Cell Survival / drug effects. Chlorambucil / pharmacology. Dose-Response Relationship, Drug. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Monocytic, Acute / drug therapy. Methylnitronitrosoguanidine / pharmacology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. RIBAVIRIN .
  • Hazardous Substances Data Bank. N-METHYL-N'-NITRO-N-NITROSOGUANIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12467305.001).
  • [ISSN] 0946-1965
  • [Journal-full-title] International journal of clinical pharmacology and therapeutics
  • [ISO-abbreviation] Int J Clin Pharmacol Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoselenium Compounds; 0 / Ribonucleosides; 12H3O2UGSF / Methylnitronitrosoguanidine; 18D0SL7309 / Chlorambucil; 49717AWG6K / Ribavirin; 83705-13-9 / selenazofurin; ULJ82834RE / tiazofurin
  •  go-up   go-down


22. Malbora B, Senel E, Avci Z, Ozbek N: Purpuric nodules and macules on the scalp of an 18-month-old boy. Skinmed; 2010 Sep-Oct;8(5):305-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cranial computed tomography revealed a small crack on the temporal bone.
  • Bone marrow aspirate results showed 68.4% blast cells and a biopsy specimen confirmed the diagnosis of acute myeloid leukemia, with flow cytometry findings positive for acute monoblastic leukemia (AML) French-American-British (FAB)-M5 phenotype.
  • We initiated induction chemotherapy for AML (AML-M5) according to the AML Berlin-Frankfurt-Munster 2004 protocol.
  • ' Complete resolution of the leukemia cutis lesions was attained with chemotherapy at the end of the first month of treatment.
  • [MeSH-major] Leukemia, Monocytic, Acute / pathology. Scalp Dermatoses / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Antigens, CD / metabolism. Antigens, CD45 / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Antineoplastic Agents / therapeutic use. Blood Cell Count. Flow Cytometry. Humans. Infant. Male. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Dandruff, Cradle Cap, and Other Scalp Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Skinmed. 2011 Jan-Feb;9(1):66
  • (PMID = 21137646.001).
  • [ISSN] 1540-9740
  • [Journal-full-title] Skinmed
  • [ISO-abbreviation] Skinmed
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antineoplastic Agents; 0 / CD68 antigen, human; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


23. Miura M, Yachie A, Hashimoto I, Okabe T, Murata N, Fukuda A, Koizumi S: Coexistence of lymphoblastic and monoblastic populations with identical mixed lineage leukemia gene rearrangements and shared immunoglobulin heavy chain rearrangements in leukemia developed in utero. J Pediatr Hematol Oncol; 2000 Jan-Feb;22(1):81-5
MedlinePlus Health Information. consumer health - Stem Cells.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistence of lymphoblastic and monoblastic populations with identical mixed lineage leukemia gene rearrangements and shared immunoglobulin heavy chain rearrangements in leukemia developed in utero.
  • Congenital leukemia often provides insight into mechanisms of in utero leukemogenesis.
  • A 10-day-old boy with clinical features of skin nodules, marked hepatosplenomegaly, and subcutaneous bleeding received a diagnosis of congenital leukemia.
  • Treatment with prednisolone, vincristine, and doxorubicin resulted in a loss of lymphoblast population and a rapid increase and dominance of the monocyte component within 10 days.
  • Complete remission initially was obtained with additional combination chemotherapy with epipodophyllotoxin (VP-16) and cytosine arabinoside (Ara-C), but relapse characterized by a lymphoblastic population in the bone marrow was subsequently observed.
  • [MeSH-major] Gene Rearrangement. Immunoglobulin Heavy Chains / genetics. Leukemia, B-Cell / congenital. Leukemia, B-Cell / pathology. Leukemia, Monocytic, Acute / congenital. Leukemia, Monocytic, Acute / pathology. Stem Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10695828.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


24. Ishii E, Kawasaki H, Isoyama K, Eguchi-Ishimae M, Eguchi M: Recent advances in the treatment of infant acute myeloid leukemia. Leuk Lymphoma; 2003 May;44(5):741-8
Genetic Alliance. consumer health - Leukemia, Myeloid.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent advances in the treatment of infant acute myeloid leukemia.
  • Infant acute myeloid leukemia (AML) of less than 12 months old is generally characterized by a high incidence of acute monoblastic or myelomonoblastic leukemia with hyperleukocytosis and extramedullary involvement.
  • The MLL gene rearrangements occur at a high frequency in monoblastic subtype, hyperleukocytosis or young age in infant AML.
  • Compared with acute lymphoblastic leukemia, however, it remains unknown whether prenatal origin exists in the pathogenesis of infant AML.
  • Recently, the treatment outcome of infant AML has been clarified by two study groups, which confirmed the effect of intensive chemotherapy including repeated cycles of cytarabine and anthracyclines for infant AML.
  • The allogeneic hematopoietic stem cell transplantation (HSCT) remains the treatment of choice for infant AML when a matched related donor is available.
  • Monitoring of minimal residual disease by real-time PCR is a useful technique to predict the outcome or efficacy of the treatment in infant AML.
  • Although intensive chemotherapy and/or allogeneic HSCT have cured most AML infants, some still relapse and ultimately die.
  • [MeSH-major] Leukemia, Myeloid / therapy
  • [MeSH-minor] Acute Disease. Antineoplastic Agents / therapeutic use. Hematopoietic Stem Cell Transplantation. Humans. Infant, Newborn. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12802909.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 89
  •  go-up   go-down


25. Chen YJ, Huang WP, Yang YC, Lin CP, Chen SH, Hsu ML, Tseng YJ, Shieh HR, Chen YY, Lee JJ: Platonin induces autophagy-associated cell death in human leukemia cells. Autophagy; 2009 Feb;5(2):173-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Platonin induces autophagy-associated cell death in human leukemia cells.
  • Platonin is a photosensitizer used for photodynamic therapy.
  • Treatment with platonin in the dark markedly reduced cell membrane integrity, and induced significant G(0)/G(1) arrest of a panel of human leukemic cell lines, including U937, HL-60, K562, NB4 and THP-1.
  • No myeloid differentiation of these cells was noted after five-day treatment.
  • Intriguingly, exposure of monoblastic U937 cells to platonin caused changes characteristic of autophagy, including appearance of cytoplasmic membranous vacuoles and formation of acidic vesicular organelles (AVO) in more than 95% of cells.
  • Platonin, other than a photodynamic agent, may offer significant promise as a therapeutic agent against leukemia.
  • [MeSH-major] Autophagy / drug effects. Leukemia / pathology. Thiazoles / pharmacology
  • [MeSH-minor] Amino Acid Chloromethyl Ketones / pharmacology. Caspases / metabolism. Cell Cycle / drug effects. Cell Differentiation / drug effects. Cell Line, Tumor. Cell Membrane / drug effects. Cell Membrane / ultrastructure. Cell Proliferation / drug effects. Cell Survival / drug effects. Cytoplasm / drug effects. Cytoplasm / metabolism. Cytoplasm / ultrastructure. Diploidy. Humans. Membrane Potential, Mitochondrial / drug effects. Microtubule-Associated Proteins / metabolism. Mitochondria / drug effects. Mitochondria / enzymology. Mitochondria / ultrastructure. Monocytes / drug effects. Monocytes / metabolism. Time Factors. Vacuoles / drug effects. Vacuoles / metabolism

  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19066447.001).
  • [ISSN] 1554-8635
  • [Journal-full-title] Autophagy
  • [ISO-abbreviation] Autophagy
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amino Acid Chloromethyl Ketones; 0 / Microtubule-Associated Proteins; 0 / Thiazoles; 0 / benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone; 0 / light chain 3, human; 0X9JDS6MF1 / platonin; EC 3.4.22.- / Caspases
  •  go-up   go-down


26. Niitsu N, Umeda M, Honma Y: Myeloid and monocytoid leukemia cells have different sensitivity to differentiation-inducing activity of deoxyadenosine analogs. Leuk Res; 2000 Jan;24(1):1-9
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloid and monocytoid leukemia cells have different sensitivity to differentiation-inducing activity of deoxyadenosine analogs.
  • The differentiation-inducing effect of clinically applicable analogs of deoxyadenosine on myelomonocytic leukemia cells was examined.
  • Monocytoid leukemia cells were more sensitive to the analogs than were erythroid or myeloid leukemia cells based on the inhibition of cell growth and induction of cell differentiation.
  • Monocytoid leukemia cells were highly sensitive to combined treatment with 2'-deoxycoformycin (dCF) and 9-beta-D-arabinofuranosyladenine (Ara A) for inducing cell differentiation.
  • Ara A induced the differentiation of monocytoid leukemia U937 and THP-1 cells at concentrations which were 1/1000-10000 of that at which it induced the differentiation of other cell lines in the presence of dCF.
  • In combination with a low concentration of 1alpha,25-dihydroxyvitamin D3 (VD3), the induction of the monocytic differentiation was greater in monoblastic U937 cells.
  • Adenosine deaminase-resistant analogs such as fludarabine (FLU) and cladribine (CdA) also induced the differentiation of human myelomonocytic leukemia cells, and these analogs synergistically enhanced the differentiation induced by all-trans retinoic acid (ATRA) or VD3.
  • CdA was the most potent analog for inducing the differentiation of myeloid leukemia NB4 and HL-60 cells in the presence or absence of ATRA.
  • These findings indicate that dCF + Ara A and CdA may be effective for the therapy of acute monocytoid and myeloid leukemia, respectively.
  • [MeSH-major] Antimetabolites, Antineoplastic / pharmacology. Cladribine / pharmacology. Leukemia, Myeloid / pathology. Monocytes / drug effects. Neoplastic Stem Cells / drug effects. Vidarabine / analogs & derivatives. Vidarabine / pharmacology
  • [MeSH-minor] Acute Disease. Adenosine Deaminase Inhibitors. Calcitriol / pharmacology. Cell Differentiation / drug effects. Deoxyadenosines / pharmacology. Dose-Response Relationship, Drug. Drug Synergism. Enzyme Inhibitors / pharmacology. HL-60 Cells / drug effects. Humans. K562 Cells / drug effects. Neoplasm Proteins / antagonists & inhibitors. Pentostatin / pharmacology. Tretinoin / pharmacology. Tumor Cells, Cultured / drug effects. U937 Cells / drug effects

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • Hazardous Substances Data Bank. CLADRIBINE .
  • Hazardous Substances Data Bank. PENTOSTATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10634639.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Adenosine Deaminase Inhibitors; 0 / Antimetabolites, Antineoplastic; 0 / Deoxyadenosines; 0 / Enzyme Inhibitors; 0 / Neoplasm Proteins; 14365-44-7 / 5'-amino-5'-deoxyadenosine; 395575MZO7 / Pentostatin; 47M74X9YT5 / Cladribine; 5688UTC01R / Tretinoin; FA2DM6879K / Vidarabine; FXC9231JVH / Calcitriol; P2K93U8740 / fludarabine
  •  go-up   go-down


27. Ginsberg JP, Orudjev E, Bunin N, Felix CA, Lange BJ: Isolated extramedullary relapse in acute myeloid leukemia: A retrospective analysis. Med Pediatr Oncol; 2002 Jun;38(6):387-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated extramedullary relapse in acute myeloid leukemia: A retrospective analysis.
  • BACKGROUND: Little is known about the characteristics and outcome of children with acute myeloid leukemia (AML) experiencing an isolated extramedullary relapse (IEMR).
  • PROCEDURE: The tumor registry of The Children's Hospital of Philadelphia identified 215 patients with AML diagnosed between 1970 and 2000, of which 16 (7.4%) experienced IEMR.
  • One survivor of IEMR received local irradiation and continued on maintenance therapy while the other five received chemotherapy, irradiation, and allogeneic marrow transplant in second or third remission.
  • CONCLUSIONS: Patients with isolated EMR are typically young males with monoblastic or myeloblastic leukemia who present with EMD at diagnosis.
  • Marrow transplant following chemotherapy and local radiotherapy offer the potential for long-term survival.
  • [MeSH-major] Leukemia, Myeloid / pathology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Male. Recurrence. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • (PMID = 11984798.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K12-CA76931; United States / NCI NIH HHS / CA / T32-CA09615
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


28. Gérard J, Berdin B, Portier G, Godon A, Tessier-Marteau A, Geneviève F, Zandecki M: [Bone marrow necrosis in two patients with neoplastic disorders]. Ann Biol Clin (Paris); 2007 Nov-Dec;65(6):636-42
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bone marrow necrosis is defined by extensive necrosis of the myeloid tissue and bone marrow stroma.
  • Within next days, the white blood cell count and the number of blasts increased, leading to the diagnosis of acute monoblastic leukaemia.
  • A chemotherapy was started but the patient died 20 days after admission.
  • According to literature, bone marrow necrosis is in most instances secondary to either an haematological malignancy (60%) or to a solid tumour (30%), but only at times observed with a non-malignant disorder.
  • Examination of the bone marrow leads to the diagnosis: cells are pycnotic, scarcely recognizable in a background of amorphous extracellular eosinophilic proteinaceous material, and histology shows disappearance of fat spaces with preservation of the bone tissue.
  • Tissue hypoxemia due to microcirculation failure may be the main mechanism leading to the necrosis, whatever the related disorder.
  • Supportive care together with specific therapy of the causal disease must be started promptly.
  • [MeSH-major] Bone Marrow / pathology. Leukemia, Monocytic, Acute / pathology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Bone marrow necrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18039608.001).
  • [ISSN] 0003-3898
  • [Journal-full-title] Annales de biologie clinique
  • [ISO-abbreviation] Ann. Biol. Clin. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


29. Rysanek B, Nicolas J, Alix T, Boutard P, Minckes O, Jeanne-Pasquier C, Bénateau H: [Mandibular chloroma]. Rev Stomatol Chir Maxillofac; 2007 Feb;108(1):68-70
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The CT-scan confirmed the rupture of the cortical bone and the extension to the soft tissue.
  • Biopsy provided the diagnosis of granulocytic monoblastic sarcoma (chloroma).
  • Chemotherapy was efficient.
  • Granulocytic monoblastic sarcoma is a localized tumor made of extramedullar immature granulocytes, in general associated (or more rarely preceded by) with leukemia.
  • Early diagnosis is important because high dose chemotherapy induction may completely cure leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mandibular Neoplasms / pathology. Sarcoma, Myeloid / pathology

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17276469.001).
  • [ISSN] 0035-1768
  • [Journal-full-title] Revue de stomatologie et de chirurgie maxillo-faciale
  • [ISO-abbreviation] Rev Stomatol Chir Maxillofac
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; BZ114NVM5P / Mitoxantrone; X4W7ZR7023 / Methylprednisolone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


30. Sunnaram BL, Gandemer V, Sebillot M, Grandgirard N, Amiot L, Leray E, Goasguen JE: LRP overexpression in monocytic lineage. Leuk Res; 2003 Aug;27(8):755-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The failure to chemotherapy is a multi factorial phenomenon and lung resistance protein (LRP) overexpression has already been discussed as implicated in drug resistance.
  • In 1996, we studied the expression of LRP and P170 (MDR) in a series of leukemias, at the time of diagnosis, by immunocytochemical (ICC) method.
  • The observation of a strong and unusual expression of LRP in acute myeloid leukemia (AML) with monocytic component led us to test (for P170 and LRP) a new series of 47 AML with different FAB subtypes.
  • We demonstrate that LRP is not correlated with clinical outcome but is statistically related to monoblastic leukemias.
  • The strongest LRP overexpression was also found in chronic myelomonocytic leukemia (four cases), reactive monocytosis (three cases) and in a dendritic cell line.
  • In conclusion, we report that LRP is rather a marker of monocytic lineage than a prognostic index for MDR and we suggest that detection of LRP by ICC could be an argument for the diagnosis of monoblastic and monocytic leukemias.
  • [MeSH-major] Leukemia, Myeloid / pathology. Monocytes / chemistry. Neoplasm Proteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12801535.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Glycoproteins; 0 / Neoplasm Proteins; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; 0 / p-170 glycoprotein, human
  •  go-up   go-down


31. Perez A, Kennedy C, Standen G, Oxley J: A case of monocytic leukaemia cutis in a patient with myelodysplastic syndrome transforming to acute myeloid leukaemia. Clin Exp Dermatol; 2004 Sep;29(5):497-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of monocytic leukaemia cutis in a patient with myelodysplastic syndrome transforming to acute myeloid leukaemia.
  • A 49-year-old woman presented with a 1-year-history of a widespread eruption which proved to be due to leukaemia cutis.
  • Subsequently, she developed pancytopaenia and a bone marrow biopsy revealed refractory anaemia with excess blasts in transformation (RAEB-T) with a high monoblastic component.
  • This transformed into acute myeloid leukaemia.
  • Leukaemia cutis in this context is well described but in this patient it became manifest 1 year prior to referral to the dermatologist.
  • When occurring with a myelodysplastic syndrome, leukaemia cutis often heralds malignant transformation to acute myeloid leukaemia.
  • Prompt diagnosis in this situation may identify a group of high-risk patients with myelodysplastic syndrome for whom chemotherapy and allogenic bone marrow transplantation, rather than the more conventional approach of supportive treatment, could be a more appropriate management strategy.
  • [MeSH-major] Anemia, Refractory, with Excess of Blasts / pathology. Leukemia / pathology. Leukemia, Myeloid, Acute / pathology


32. Salih HR, Starling GC, Brandl SF, Pelka-Fleischer R, Haferlach T, Hiddemann W, Kiener PA, Nuessler V: Differentiation of promyelocytic leukaemia: alterations in Fas (CD95/Apo-1) and Fas ligand (CD178) expression. Br J Haematol; 2002 Apr;117(1):76-85
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation of promyelocytic leukaemia: alterations in Fas (CD95/Apo-1) and Fas ligand (CD178) expression.
  • The survival of leukaemic blasts contributes to the pathological mechanism of acute promyelocytic leukaemia (APL).
  • While treatment of APL using retinoic acid (RA) is a model of differentiation therapy, little is known about possible effects of this treatment on the Fas/FasL system.
  • Investigation of APL cells from patients undergoing differentiation therapy with RA and of promyelocytic HL-60 and monoblastic U-937 cells cultured with RA revealed a reduction of surface expression of both Fas and its ligand.
  • Our findings demonstrate that there are significant changes in Fas and FasL expression during RA treatment of APL, which probably have consequences for the interaction between host immune and leukaemia cells, and thus may be involved in the beneficial effects of differentiation therapy.
  • [MeSH-major] Antigens, CD95 / analysis. Antineoplastic Agents / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Leukemia, Promyelocytic, Acute / immunology. Membrane Glycoproteins / analysis. Tretinoin / therapeutic use
  • [MeSH-minor] Apoptosis / drug effects. Blotting, Western / methods. Cell Differentiation / drug effects. Coculture Techniques. Fas Ligand Protein. Flow Cytometry. HL-60 Cells. Humans. Jurkat Cells. U937 Cells

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11918536.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Antineoplastic Agents; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Membrane Glycoproteins; 5688UTC01R / Tretinoin
  •  go-up   go-down






Advertisement